Buy Thymagen (Thymogen) Research Peptide

Thymogen, also known by its dipeptide designation EW (Glu-Trp), is a synthetic dipeptide bioregulator with a molecular weight of 333.34 g/mol. Defined by the amino acid sequence Glu-Trp (L-Glutamyl-L-Tryptophan), Thymogen was subsequently isolated via reversed-phase HPLC as the active dipeptide component of Thymalin — the calf-thymus peptide complex developed in the 1970s by Vladimir Khavinson and Vyacheslav Morozov at the Kirov Military Medical Academy in Leningrad — and has since been studied as one of several ultra-short synthetic peptide bioregulators characterized at the Saint Petersburg Institute of Bioregulation and Gerontology. Its structure pairs an acidic glutamic acid residue with the aromatic indole-containing tryptophan residue, a combination that has been the subject of structure-function investigation in the context of thymic peptide signaling.

Thymogen has been investigated in preclinical immunology as a dipeptide bioregulator; its precise molecular mechanism of action has not been fully established, and published studies to date have characterized its downstream effects on immune-cell signaling pathways rather than identifying a defined receptor target. In vitro studies in a human monocyte/macrophage cell line have examined the Glu-Trp dipeptide’s modulation of proliferative activity and inflammatory signaling, documenting effects on MAPK (ERK1/2, JNK) phosphorylation and characterizing reduced secretion of pro-inflammatory cytokines (including TNF-α and IL-6) as a primary readout of the dipeptide’s interaction with immune cell populations [1]. In vivo rodent studies have examined L-glutamyl-L-tryptophan as an immune-mediated antitumour agent, documenting tumor-growth suppression in mice despite the absence of direct tumor-cell cytotoxicity in culture. The study characterized this activity as dependent on NK/NKT-cell cytolytic function, perforin and IL-12 signaling, consistent with an interaction with innate immune effector mechanisms in controlled preclinical tumor models [2], making Thymogen a key reference compound in thymic-peptide research examining minimal-sequence dipeptide modulation of immune cell signaling in preclinical models.

Thymogen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available to view and download directly on the product page.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 11 August 2026

View credentials →